Plasma-derived exosomes from patients with obstructive sleep apnea contributes to cardiovascular disease through miR-181b-5p-TNF-α signaling

Objective: Obstructive sleep apnea (OSA) is characterized by intermittent hypoxemia with re-oxygenation (IHR) leading to systemic inflammation, and associated increased risk for cardiovascular diseases (CVD). We hypothesized that plasma-derived exosomes may contribute to CVD in OSA through targeting tumor necrosis factor- α via microRNA (miR)-181b-5p.

Method: Exosomes and peripheral blood mononuclear cells (PBMCs) from 38 OSA patients with CVD, 34 OSA patients without CVD and 14 subjects with primary snoring (PS) were assessed.

Results: TNF- α gene expression levels of PBMCs and the release of TNF- α from human umbilical vein endothelial cell lines (HUVEC) in response to stimuli with plasma-derived exosomes were both increased in OSA patients versus PS subjects, and further increased in OSA patients with CVD versus those without CVD, while miR181b-5p gene expression of PBMCs and cell viability of HUVEC were decreased. TNF- α release with exosome stimulation was positively correlated with snoring index and left atrial size, and negatively correlated with minimum oxyhemoglobin saturation. Plasma-derived exosomes from OSA patients inhibited gene expressions of several cell junction-related molecules, including ZO-1, ZO-2, Nectin-3 Occludin, β -catenin, VE-cadherin, PECAM-1, and GJA1, and augmented endothelial monolayer permeability of HUVEC versus PS group.

Conclusions: Exosome-mediated miR-181b inhibition via targeting TNF- α is associated with the development of CVD in OSA patients, probably through destroying cell barrier and enhancing permeability of endothelium.